Arrowhead Pharmaceuticals, Inc. (ARWR): Price and Financial Metrics
Today's Latest Price: $57.30 USD
Oct 30 4:00pm Add ARWR to Watchlist Sign Up
Buy & Hold Grade
Peer Grade Industry Rank
ARWR Stock Summary With a price/sales ratio of 47.4, Arrowhead Pharmaceuticals Inc has a higher such ratio than 95.8% of stocks in our set. ARWR's equity multiplier -- a measure of assets relative to shareholders'equity -- is greater than that of just 11.82% of US stocks. Over the past twelve months, ARWR has reported earnings growth of -182.7%, putting it ahead of just 10.56% of US stocks in our set. Stocks with similar financial metrics, market capitalization, and price volatility to Arrowhead Pharmaceuticals Inc are CUE, BLUE, ARVN, ZYME, and ACRS. ARWR's SEC filings can be seen here. And to visit Arrowhead Pharmaceuticals Inc's official web site, go to arrowheadpharma.com.
ARWR Price/Volume Stats
Arrowhead Pharmaceuticals, Inc. (ARWR) Company Bio
Arrowhead Pharmaceuticals is a biopharmaceutical company developing targeted RNAi therapeutics. The company was founded in 1989 and is based in Pasadena, California.
ARWR Latest News Stream
All News Types
Commentary Corp. News Downgrade Earnings New Coverage (Bullish) New Coverage (Neutral) Product News PT Lowered PT Raised PT Set (Bearish) PT Set (Bullish) Rating Reiterated (Bullish) Rating Reiterated (Neutral) Stock Offering Upgrade
Loading, please wait...
Latest ARWR News From Around the Web
Below are the latest news stories about Arrowhead Pharmaceuticals Inc that investors may wish to consider to help them evaluate ARWR as an investment opportunity.
This research report acknowledges the presentation segments of the global market. The market was classified in terms of presentation in the next piece. The report highlights substantial market growth trends and dynamics, including limitations, drivers and opportunities. A number of
PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead to participate in Chardan Genetic Medicines Conference
Gainers: Arrowhead Pharmaceuticals (ARWR) +47%.Eastman Kodak (KODK) +39%.Myomo (MYO) +35%.Inovio Pharmaceuticals (INO) +27%.Renren (RENN) +25%.AMC Networks (AMCX) +22%.Pacific Ethanol (PEIX) +22%.Histogen (HSTO) +21%.Heat Biologics (HTBX) +16%.Ossen Innovation (OSN) +16%.Losers: Novus Therapeutics (NVUS) -17%.ADT (ADT) -13%.American Axle & Manufacturing (AXL) -12%.Forterra (FRTA) -10%.8i Enterprises Acquisition (JFK) -10%.Francesca's (FRAN) -10%.Grupo Supervielle (SUPV) -9%.89bio (ETNB) -9%.Jounce Therapeutics (JNCE) -9%.Empresa Distribuidora (EDN) -6%....
Gainers: Arrowhead Pharmaceuticals (ARWR) +46%, Myomo (MYO) +38%, AxoGen (AXGN) +15%, Covetrus (CVET) +14%, Inovio Pharmaceuticals (INO) +13%.Losers: Novus Therapeutics (NVUS) -13%, Jounce Therapeutics (JNCE) -10%, Syneos Health (SYNH) -7%, Verastem (VSTM) -5%, Evogene (EVGN) -5%....
Arrowhead Pharmaceuticals (NASDAQ: ARWR) shares are trading higher on Wednesday after the company announced positive interim 24-week liver biopsy results in …
Read More 'ARWR' Stories Here
ARWR Price Returns
Get Free Updates
Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!
Page generated in 0.7424 seconds.